This week's member activity

A quick summary of ideas that you have added to the cancer immune-setpoint - plus some questions that we need your help to answer.

Go to the profile of Dr Alison Halliday
Jan 28, 2018
0
Comment

As cancer immunotherapy is a rapidly evolving field of research, keeping the framework up to date – improving on what’s included and adding new data when it gets published - will only be achieved through a collective effort from everyone involved.

Please read my post summarising the ideas that members of our community have added so far.

And to re-highlight - a couple of members have posed some specific questions last week that we need your help to answer:

  • On step 7, on the anti-BCL2 family members factors, Jose asks:

"What criteria drive the selection of a cell-death pathway in immunotherapy?"

  • On step 5, chemokines, Veronika asks: 

"How come chemokines are noted down with negative effects? The CXCR3/CXCR3 ligand axis, for instance, has been shown to recruit T and NK cells into tumors in mouse studies and has been associated with T cell infiltration in several human studies."

Are you an expert on these topics –  if so, can you help answer their questions?

Don’t be shy - please go to the website (on a computer rather than mobile) and add to or comment on the interactive framework. All contributions are welcome, no matter how big or small!

Please see our ‘how to’ post if you need a quick reminder about what you need to do.

Go to the profile of Dr Alison Halliday

Dr Alison Halliday

Community Manager, Nature Research

Molecular Biologist turned freelance science communicator, with 10 year's experience at Cancer Research UK.

No comments yet.